Viatris Earns $25M Yupelri Milestone on $266.6M 2025 Sales Growth
Viatris received a $25 million milestone payment in January 2026 under its collaboration with Theravance Biopharma after Yupelri net sales reached $266.6 million in 2025, a 12% year-over-year increase. Theravance’s organizational restructuring will sharpen focus on Yupelri commercialization, potentially boosting Viatris’s royalty revenue stream.
1. Partnership Milestone Payment
In January 2026, Viatris received a $25 million milestone payment from Theravance Biopharma under their commercial collaboration for Yupelri. This payment followed full-year 2025 net sales of $266.6 million for Yupelri, representing a 12% year-on-year increase.
2. Restructuring to Sharpen Yupelri Focus
Theravance Biopharma announced a restructuring to cut R&D and administrative costs by shutting down its R&D division and halving G&A staff, aiming to focus resources on Yupelri’s commercialization. This strategic shift could enhance sales support and royalty streams for Viatris under the partnership agreement.